If you or a loved one is facing a certain type of cancer, you might be asking, what is car t therapy? CAR T therapy is a groundbreaking treatment that reprograms a patient’s own immune cells to fight certain cancers. It represents a major shift from traditional approaches like chemotherapy. This article explains how it works, who it can help, and what the process involves.
What Is Car T Therapy
CAR T-cell therapy, or chimeric antigen receptor T-cell therapy, is a type of immunotherapy. It is not a pill or a radiation beam. Instead, it is a living drug made from your own white blood cells. Doctors genetically modify these cells in a lab to better recognize and destroy cancer cells. The treatment is highly personalized and has shown remarkable success where other treatments have failed.
The Science Behind Car T Cells
To understand CAR T therapy, you need to know a bit about T-cells. These are a critical part of your immune system. They patrol your body looking for infections and abnormal cells, like cancer. However, cancer cells are clever. They can disguise themselves or shut down the immune response. This allows them to grow unchecked.
CAR T therapy supercharges your T-cells. Scientists add a new gene to them. This gene instructs the cell to produce a special protein on its surface called a chimeric antigen receptor (CAR). This CAR acts like a highly precise GPS and weapon system combined. It is designed to lock onto a specific protein, or antigen, found on the surface of the cancer cells.
Key Components Of The Car Construct
- Antigen-Binding Domain: This is the part that recognizes and attaches to the cancer cell’s specific antigen.
- Spacer/Hinge Region: This gives the receptor flexibility to reach its target.
- Transmembrane Domain: This anchors the CAR into the T-cell’s own membrane.
- Signaling Domains: These are the “on switches” that activate the T-cell once the target is found, triggering it to attack and multiply.
How The Car T Therapy Process Works
The treatment is complex and involves several key steps. It typically takes a few weeks from start to finish. The process is managed by a specialized medical team at an accredited treatment center.
- Leukapheresis: First, your blood is drawn through a machine that separates out your T-cells. The rest of your blood is returned to your body. This is an outpatient procedure.
- Engineering and Manufacturing: Your T-cells are frozen and sent to a central laboratory. There, they are genetically modified to express the CAR protein. They are then grown into the millions to create a potent dose. This manufacturing step is crucial and can take several weeks.
- Lymphodepletion Chemotherapy: Before you get your cells back, you usually receive a short course of chemotherapy. This is not to directly treat the cancer, but to make room in your immune system for the new CAR T-cells to expand and work effectively.
- Infusion: Your newly engineered CAR T-cells are thawed and infused back into your bloodstream, similar to a blood transfusion. This is often a simple procedure, but you will be monitored closely afterwards.
- Monitoring and Recovery: After the infusion, the CAR T-cells multiply and begin attacking the cancer. You will need to stay near the treatment center for several weeks for intensive monitoring of side effects and treatment response.
Cancers Currently Treated With Car T Therapy
CAR T therapy is not yet a universal cancer treatment. It is approved by the U.S. Food and Drug Administration (FDA) for specific blood cancers. Researchers are actively testing it for other cancers, including solid tumors like breast or lung cancer, but these are still in clinical trials.
- B-cell Acute Lymphoblastic Leukemia (ALL): This was the first cancer approved for CAR T therapy in children and young adults.
- Diffuse Large B-cell Lymphoma (DLBCL): This is the most common type of non-Hodgkin lymphoma in adults.
- Follicular Lymphoma: A slower-growing type of non-Hodgkin lymphoma.
- Multiple Myeloma: A cancer of plasma cells in the bone marrow.
- Mantle Cell Lymphoma: Another form of non-Hodgkin lymphoma.
The common thread among these cancers is that they often express a protein called CD19 on their surface. Most currently approved CAR T therapies are designed to target the CD19 antigen. For multiple myeloma, the target is a different protein called BCMA.
Potential Benefits And Remarkable Outcomes
The benefits of CAR T-cell therapy can be profound, especially for patients with few other options. In pivotal clinical trials, many patients who had exhausted all standard treatments achieved complete remission, meaning no detectable cancer. For some, this remission has lasted for years, offering what doctors hope could be a long-term cure. The therapy’s precision also means it can potentially avoid some of the widespread damage to healthy tissues caused by conventional chemotherapy.
Understanding The Risks And Side Effects
Like all powerful cancer treatments, CAR T therapy carries significant risks. The side effects can be severe and require expert management in a hospital setting. Two major side effects are closely watched.
Cytokine Release Syndrome (CRS)
This is the most common side effect. As the CAR T-cells multiply and attack the cancer, they release a flood of immune chemicals called cytokines into the bloodstream. This can cause a systemic inflammatory response. Symptoms can range from mild to life-threatening and may include:
- High fever and chills
- Severe fatigue
- Nausea and vomiting
- Muscle and joint pain
- Low blood pressure
- Difficulty breathing
Doctors have become very adept at managing CRS with supportive care and specific medications like tocilizumab.
Neurological Toxicities (ICANS)
This side effect, sometimes called ICANS (Immune Effector Cell-Associated Neurotoxicity Syndrome), affects the nervous system. Symptoms can include:
- Headache
- Confusion or agitation
- Difficulty speaking or understanding speech
- Tremors or seizures
- In rare cases, brain swelling
Other potential risks include a weakened immune system and increased risk of infections for a prolonged period, low blood cell counts (cytopenias), and the possibility that the treatment may not work for every patient. It’s also possible for the cancer to eventually return, sometimes by losing the target antigen that the CAR T-cells recognize.
What To Expect After Treatment
Recovery and follow-up are long-term commitments. After the initial monitoring period near the treatment center, you will need frequent check-ups. Your doctor will perform tests like PET scans and bone marrow biopsies to see if the cancer is in remission. Because your immune system is affected, you may need preventative antibiotics and immunoglobulin replacement therapy for months. You will also recieve guidance on avoiding infections, such as staying up to date on vaccinations (with inactivated vaccines only) and avoiding crowds initially.
The Future Of Car T Therapy
Research is moving rapidly to make CAR T therapy safer, more effective, and more widely available. Scientists are working on “off-the-shelf” CAR T products made from healthy donor cells, which could reduce cost and wait time. They are also developing dual-target CARs to prevent cancer escape, and are trying to engineer cells that are more persistent and less prone to causing severe side effects. The biggest challenge remains applying this technology to solid tumors, which have a more complex environment that shields them from immune attack.
Frequently Asked Questions
How much does CAR T-cell therapy cost?
CAR T therapy is extremely expensive, often costing hundreds of thousands of dollars. This includes the cost of manufacturing the cells, the hospital stay, and management of side effects. However, most insurance plans, including Medicare, now cover FDA-approved CAR T therapies for their indicated uses, but pre-authorization is always required.
Is CAR T therapy considered a cure for cancer?
For some patients, it has led to long-term remission that appears to be curative. However, it is too early to say it is a definitive cure for all who recieve it. Doctors use terms like “durable remission” or “potential for cure,” as long-term data is still being collected. Results vary by cancer type and individual patient factors.
What is the success rate of CAR T therapy?
Success rates vary by the specific cancer and the product used. In clinical trials for relapsed/refractory large B-cell lymphoma, for example, complete response rates have ranged from about 40% to over 50%. It’s important to discuss the specific statistics relevant to your situation with your oncologist.
How long does it take to make CAR T-cells?
The manufacturing process typically takes between 2 to 4 weeks. This time is needed to genetically modify the cells and grow them to sufficient numbers. This period can be stressful for patients waiting for treatment, and their disease is sometimes managed with bridging therapy.
What is the difference between CAR T therapy and a bone marrow transplant?
Both are used for blood cancers, but they work differently. A bone marrow transplant (or stem cell transplant) replaces your entire immune system with a donor’s to fight cancer. CAR T therapy supercharges your own specific immune cells (T-cells) to target the cancer. CAR T therapy is generally less intensive than a transplant but comes with its own unique set of side effects.